Results 11 to 20 of about 395,005 (295)
Validity of the ESC Risk Assessment in Idiopathic Pulmonary Arterial Hypertension in China
Frontiers in Cardiovascular Medicine, 2021 Background: The 2015 European pulmonary hypertension (PH) guidelines recommend a risk stratification strategy for pulmonary arterial hypertension (PAH).
Su-Gang Gong +9 more
doaj +1 more source
Trials, 2021 Background Management of inoperable chronic thromboembolic pulmonary hypertension (CTEPH) remains a clinical challenge. Currently, riociguat, a soluble guanylate-cyclase stimulator is recommended by international guidelines.
Qin-Hua Zhao +12 more
doaj +1 more source
Frontiers in Cardiovascular Medicine, 2021 Background: Patients with chronic thromboembolic pulmonary hypertension (CTEPH) still experience reduced exercise capacity despite pulmonary endarterectomy (PEA). Exercise training improves the exercise capacity and quality of life (QoL) in patients with
Ya-Lin Zhao +10 more
doaj +1 more source
BMC Cardiovascular Disorders, 2022 Background Pulmonary hypertension in left heart disease (PH-LHD), which includes combined post- and precapillary PH (Cpc-PH) and isolated postcapillary PH (Ipc-PH), differs significantly in prognosis.
Xiu-Jun Zhong +13 more
doaj +1 more source
Respiratory Research, 2022 Background Our previous study showed that circular RNA-gamma-secretase-activating protein (circGSAP) was down-regulated in pulmonary microvascular endothelial cells (PMECs) in response to hypoxia, and regulated the cell cycle of PMECs via miR-942-5p ...
Yuanyuan Sun +11 more
doaj +1 more source
Frontiers in Cardiovascular Medicine, 2022 BackgroundThere is little evidence of the effectiveness of switching from the endothelin receptor antagonists (ERAs) bosentan and ambrisentan to a novel ERA, macitentan, in patients with pulmonary arterial hypertension (PAH).
Jie Li +14 more
doaj +1 more source
BMJ Open, 2021 Objectives The aim was to elucidate the relationship between liver function and idiopathic pulmonary arterial hypertension (IPAH).Design and setting Retrospective, longitudinal study in urban tertiary care centre in Shanghai, China.Participants 407 IPAH ...
Rui Zhang +12 more
doaj +1 more source
Animal Models and Experimental Medicine, 2022 Background Aberrant expression of microRNAs (miRNAs) has been associated with the pathogenesis of pulmonary hypertension (PH). It is, however, not clear whether miRNAs are involved in estrogen rescue of PH. Methods Fresh plasma samples were prepared from
Xiaoyi Hu +8 more
doaj +1 more source
Frontiers in Cardiovascular Medicine, 2021 Background: Right ventricular (RV) function is a great determination of the fate in patients with pulmonary arterial hypertension (PAH). Monitoring RV structure back to normal or improvement should be useful for evaluation of RV function.
Qin-Hua Zhao +11 more
doaj +1 more source
Transient but not genetic loss of miR-451 attenuates the development of pulmonary arterial hypertension [PDF]
, 2013 <b>Rationale:</b> MicroRNAs are small non-coding RNAs involved in the regulation of gene expression and have recently been implicated in the development of pulmonary arterial hypertension (PAH).
Baker, Andrew H. +5 more
core +5 more sources